Olmesartan medoxomil/azelnidipine

Drug Profile

Olmesartan medoxomil/azelnidipine

Alternative Names: Azelnidipine/olmesartan medoxomil; CS-866AZ; Rezaltas

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antihypertensives; Dihydropyridines; Imidazoles; Imino acids; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 16 Apr 2010 Launched for Hypertension in Japan (PO)
  • 21 Jan 2010 Registered for Hypertension in Japan (PO)
  • 11 Dec 2008 Preregistration for Hypertension in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top